Highlights of ESC HF 2021 - AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting

AFFIRM-AHF-based multinational cost-effectiveness analysis of intravenous ferric carboxymaltose for the treatment of iron deficiency in an acute heart failure setting Heart Failure utilizes major resources and is an economic burden on healthcare systems. Iron deficiency is prevalent in 50% of patients with chronic HF and in 80% of patients hospitalized for acute HF. It is associated with poor functional status and increased risk of adverse outcomes in HF patients, thus Iron deficiency in HF is an area of significant unmet need. In the AFFIRM-AHF trial, patients hospitalized for acute HF with LVEF <50%, having iron deficiency and Hb level between 8-15g/dl were randomized to either placebo or Ferric Carboxy maltose (FCM) and followed periodically for 52 weeks. The primary outcome was a composite of HHF and CV death, and Secondary outcomes were total HF hospitalization, CV death, and most importantly change from baseline in Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-CSS). The outcome analysis showed that the Primary composite Endpoint was not met with a significance value of less than 5%. But the total HF hospitalization events were significantly reduced with p-value of 0.013 and a risk reduction of 11 events per 100 patient years. The KCCQ-CSS score at baseline was 40, and significant improvement was seen between the 4th and 24 weeks compared to the placebo. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.